Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Voss

Showing results (181-190 of 194) with videos related to

Pageof 20
Sort By:
Pathogens & Immunity|October 27, 2025
Meeting Summary for Keystone Symposia on HIV Cure: Antiretroviral Therapy (ART)-Free Control of HIV Infection in Durban, South Africa, 2025Kiho Tanaka, Tatenda Jimmy Blessing Chikowore, Steven G Deeks, et al.
Mabs|March 5, 2014
Antibody engineering and therapeutics, The Annual Meeting of the Antibody Society: December 8-12, 2013, Huntington Beach, CAJuan Carlos Almagro, Gary L Gilliland, Felix Breden, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 3, 2020
B cells expressing authentic naive human VRC01-class BCRs can be recruited to germinal centers and affinity mature in multiple independent mouse modelsDeli Huang, Robert K Abbott, Colin Havenar-Daughton, et al.
Biorxiv : the Preprint Server for Biology|November 25, 2020
An Engineered Antibody with Broad Protective Efficacy in Murine Models of SARS and COVID-19C Garrett Rappazzo, Longping V Tse, Chengzi I Kaku, et al.
Biorxiv : the Preprint Server for Biology|June 9, 2020
Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal modelThomas F Rogers, Fangzhu Zhao, Deli Huang, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 11, 2001
Photochemically enhanced binding of small molecules to the tumor necrosis factor receptor-1 inhibits the binding of TNF-alphaP H Carter, P A Scherle, J K Muckelbauer, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 20, 2014
Live simian immunodeficiency virus vaccine correlate of protection: local antibody production and concentration on the path of virus entryQingsheng Li, Ming Zeng, Lijie Duan, et al.
Science (New York, N.Y.)|January 26, 2021
Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibodyC Garrett Rappazzo, Longping V Tse, Chengzi I Kaku, et al.
Journal of Medicinal Chemistry|July 27, 2001
Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivoC B Xue, M E Voss, D J Nelson, et al.
Journal of Medicinal Chemistry|October 29, 2021
Discovery of <b>MK-4688</b>: an Efficient Inhibitor of the HDM2-p53 Protein-Protein InteractionMichael H Reutershan, Michelle R Machacek, Michael D Altman, et al.
Pageof 20

Showing results (181-190 of 194) with videos related to

Sort By:
Pageof 20
Pathogens & Immunity|October 27, 2025
Meeting Summary for Keystone Symposia on HIV Cure: Antiretroviral Therapy (ART)-Free Control of HIV Infection in Durban, South Africa, 2025Kiho Tanaka, Tatenda Jimmy Blessing Chikowore, Steven G Deeks, et al.
Mabs|March 5, 2014
Antibody engineering and therapeutics, The Annual Meeting of the Antibody Society: December 8-12, 2013, Huntington Beach, CAJuan Carlos Almagro, Gary L Gilliland, Felix Breden, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 3, 2020
B cells expressing authentic naive human VRC01-class BCRs can be recruited to germinal centers and affinity mature in multiple independent mouse modelsDeli Huang, Robert K Abbott, Colin Havenar-Daughton, et al.
Biorxiv : the Preprint Server for Biology|November 25, 2020
An Engineered Antibody with Broad Protective Efficacy in Murine Models of SARS and COVID-19C Garrett Rappazzo, Longping V Tse, Chengzi I Kaku, et al.
Biorxiv : the Preprint Server for Biology|June 9, 2020
Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal modelThomas F Rogers, Fangzhu Zhao, Deli Huang, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 11, 2001
Photochemically enhanced binding of small molecules to the tumor necrosis factor receptor-1 inhibits the binding of TNF-alphaP H Carter, P A Scherle, J K Muckelbauer, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 20, 2014
Live simian immunodeficiency virus vaccine correlate of protection: local antibody production and concentration on the path of virus entryQingsheng Li, Ming Zeng, Lijie Duan, et al.
Science (New York, N.Y.)|January 26, 2021
Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibodyC Garrett Rappazzo, Longping V Tse, Chengzi I Kaku, et al.
Journal of Medicinal Chemistry|July 27, 2001
Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivoC B Xue, M E Voss, D J Nelson, et al.
Journal of Medicinal Chemistry|October 29, 2021
Discovery of <b>MK-4688</b>: an Efficient Inhibitor of the HDM2-p53 Protein-Protein InteractionMichael H Reutershan, Michelle R Machacek, Michael D Altman, et al.
Pageof 20